AstraZeneca’s stock price saw a sharp decline of 9% on Monday following a report by the Financial Times suggesting the company was in preliminary talks to acquire U.S.-based pharmaceutical firm Bristol Myers Squibb. Had the deal proceeded, it would have created a massive $400 billion pharmaceutical entity. However, the market sentiment shifted again on Wednesday after Reuters reported that there were no active discussions between the two companies. This update prompted a partial recovery in AstraZeneca’s share price.

The lack of official communication from either AstraZeneca or Bristol Myers Squibb has left investors and analysts to speculate on the nature of these reports. It remains unclear whether the companies engaged in informal exploratory talks that were subsequently abandoned, or if the reports were based on inaccurate information. The volatility highlights the sensitivity of pharmaceutical stock prices to rumors of large-scale consolidation, as investors weigh the potential benefits of such a merger against the significant financial risks and integration challenges inherent in a deal of this magnitude.